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Abstract 
Background: Drugs that kill or inhibit Plasmodium gametocytes in the human host could potentially synergize the 
impact of other chemotherapeutic interventions by blocking transmission. To develop such agents, reliable methods 
are needed to study the in vitro activity of compounds against gametocytes. This study describes a novel assay for 
characterizing the activity of anti‑malarial drugs against the later stages of Plasmodium falciparum gametocyte devel‑
opment using real‑time PCR (qPCR).
Methods: Genes previously reported to be transcribed at the different sexual stages of the gametocytogenesis were 
selected for study and their mRNA expression was measured in a gametocytogenesis course by qPCR. Genes mainly 
expressed in the later stages of gametocyte development were used as a surrogate measurement of drug activity. To 
distinguish between cidal and static drug effects, two different experiments were performed in parallel, one with con‑
stant drug pressure throughout the experiment (144 h), and another in which the gametocyte cultures were exposed 
to the compound for only 48 h.
Results: Four P. falciparum genes coding for proteins Pf77, ROM3, Pfs25, and Pfg377 with transcription specific for 
late‑stage gametocyte development were identified. The in vitro anti‑malarial activity of compounds against such 
gametocytes was assessed by measuring mRNA levels of these genes using qPCR. The assay was validated against 
standard anti‑malarial drugs (epoxomicin, dihydroartemisinin, chloroquine, thiostrepton, and methylene blue) and 
compounds from the GSK compound library with known anti‑gametocyte activity.
Conclusions: This study describes a novel assay for characterizing the activity of anti‑malarial drugs against the 
later stages of P. falciparum gametocyte development using qPCR in genetically unmodified parasites. The method 
described is a reliable and user‑friendly technique with a medium throughput that could be easily implemented in 
any laboratory.
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Background
Malaria remains one of the most widespread infectious 
diseases and a major global health problem. In 2015, 
there were an estimated 214 million malaria cases, with 
438,000 deaths [1]. Malaria is caused by protozoan para-
sites of the genus Plasmodium. Parasite asexual stages 
cause the clinical symptoms of malaria, and the sexual 
stages (gametocytes) allow transmission of the parasite 
from human to mosquito.
Transmission blocking is a key strategy highlighted 
in the Malaria Eradication Research Agenda (malERA) 
[2]. In the absence of an effective transmission-blocking 
vaccine, chemotherapy remains a cornerstone of cur-
rent interventions [3]. Although many of the classical 
anti-malarial drugs are active against early gametocyte 
stages, mature gametocytes are unresponsive to these 
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drugs. Currently, only primaquine, an 8-aminoquinoline, 
is approved for clinical use as a transmission-blocking 
agent. However, primaquine has toxicity issues, caus-
ing haemolysis in glucose-6-phosphate dehydrogenase 
(G6PD)-deficient individuals [4, 5].
Future anti-malarial treatments should ideally target 
both the rapidly replicating asexual stages and the less 
metabolically active, non-replicating, mature gameto-
cytes. Recently, several in  vitro assays have been devel-
oped that allow the investigation of drug activity during 
gametocytogenesis and against sexual forms [6–12]. 
However, there remains a need to confirm the cidal effect 
of new compounds on mature gametocytes prior to vali-
dating their transmission-blocking potential ex vivo using 
the standard membrane-feeding assay (SMFA).
Detecting and quantifying specific mRNA levels 
directly reflects gene expression and is, therefore, a hall-
mark of viable cells. A real-time PCR (qPCR) assay was 
previously reported, focused on asexual stages, that 
allows classification of compound anti-malarial activ-
ity as ‘cidal’ or ‘static’, using mRNA expression levels as 
a surrogate of parasite viability [13]. In the asexual stage 
assay, a drug was considered ‘static’ if the active growth of 
parasites was arrested in its presence, but resumed once 
drug was removed from the medium. A drug was consid-
ered ‘cidal’ if parasite growth was not resumed following 
the removal of drug pressure, evidenced by a significant 
reduction in mRNA expression levels (more than 100 
times vs untreated controls). In the context of gameto-
cytes, cidal compounds are those that produce irrevers-
ible changes in the parasite that are sustained once the 
compound is removed; ‘static’ compounds are those that 
exert a deleterious effect only when the compound is pre-
sent. However, because of the low metabolism of gameto-
cytes, mRNA levels will not recover.
The objective of this study was to further develop the 
above assay to allow quantitative analysis of the levels 
of late-stage gametocyte-specific mRNAs. The robust 
identification of genes specific expressed during the later 
stages of gametocyte development, different from those 
detected in asexual forms and young gametocytes, was 
therefore critical to support the use of qPCR to distin-
guish molecules active against late-stage gametocytes. 
Plasmodium falciparum gametocytogenesis lasts about 
8–12  days, and has been traditionally divided into five 
distinct morphological stages corresponding to differ-
ent phases of maturation [14, 15]. Microarray experi-
ments have demonstrated fluctuating mRNA levels for 
many genes through the parasite lifecycle, discerning the 
expression of several genes as stage specific [16–19], with 
some confirmed by qPCR [20–22].
In this study, a snapshot of the expression profile of the 
12 best-described candidate genes for identifying mature 
gametocytes was generated. Having identified genes 
expressed specifically during the later stages of gameto-
cyte development, the methodology already established 
to classify compounds with cidal activity for asexual 
stages could be extended to identify those with gameto-
cytocidal activity. This assay was validated using com-
mercially available anti-malarial drugs plus compounds 
with proven transmission-blocking activity selected from 
the corporate GSK compound collection [23].
Methods
Chemicals
All commercially available and GSK compounds previ-
ously characterized as anti-malarial agents were dis-
solved in H2O or dimethyl sulfoxide (DMSO, SIGMA, 
Steinheim, Germany) at variable stock concentrations. 
All stock solutions were kept at −20 °C.
Parasite culture
Plasmodium falciparum chloroquine-sensitive strain 
3D7A was obtained from the Malaria Research and Ref-
erence Reagent Resource Center (MR4) and was main-
tained in continuous culture at 4  % haematocrit using 
fresh AB+ erythrocyte concentrates provided by the 
Spanish Red Cross blood bank of Madrid, Spain. Game-
tocyte production and maturation followed the proto-
col published by Lelievre et  al. [24]. Two independent 
gametocytogenesis courses were performed, maintaining 
cultures for 15 and 30 days. Both parasitaemia and game-
tocyte maturation were monitored by thin blood smears 
stained with 10  % Giemsa (Merck) in phosphate buffer 
pH 7.2. During the time course, 200  µl of total parasite 
culture (12 % haematocrit) was harvested daily, pelleted 
down and then stored at −80  °C for subsequent qPCR 
analysis. Sampling was performed in duplicate.
As an alternative to the standard procedure described 
[24], gametocytes were cultured for 20  days adding 
50  ng/ml bistratene A to the cultures twice a day from 
day 4 to remove the asexual stages earlier. One millilitre 
of culture at 12 % haematocrit was pelleted on days 1, 4, 
7, 15, and 20 and then stored at −80 °C for analysis.
Cidal vs static activity assay
The in  vitro cidal or static anti-malarial activity of a 
compound against the later stages of gametocyte devel-
opment at day 15 was assessed by measuring mRNA 
levels in P. falciparum over 144  h following drug treat-
ment (Fig. 1). Drug activity assays were performed once 
in two independent cultures in T-75 flasks (Corning, 
NY, USA). Late-stage gametocytes were incubated with 
drug and 6  % haematocrit over 48  h. Compounds were 
used at a concentration of a minimum of 20-fold their 
IC50 against mature gametocytes (20  ×  IC50), with the 
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exceptions of methylene blue, tested at ten times its 
IC50, epoxomicin, tested at two times its IC50, and chlo-
roquine, tested at 5 µM corresponding to 125 times the 
asexual IC50; concentrations are specified in Table 1. IC50 
values were obtained from Lelievre et al. [24]. To remove 
drug from the medium, parasite cultures were harvested 
and washed two times with 25  ml of RPMI. After drug 
removal, the parasites were cultured for a further 96  h 
with complete culture medium either without or with 
drug, at the same concentration as the initial incuba-
tion, to evaluate the reversibility of the compound effect. 
Medium was changed daily and two samples of 1000 µl 
of culture at 0, 48, 96, and 144 h were taken, centrifuged 
and immediately stored at −80 °C for further analysis. An 
untreated culture was used as a positive control. 
RNA extraction and cDNA reverse transcription
For RNA extraction, RNeasy Plus mini kit (Qiagen, 
Hilden, Germany) was used according to the stand-
ard protocol supplied by the manufacturer. cDNA 
synthesis and SYBR green qPCR were performed in 
duplicate following the protocol already published by 
Bahamontes-Rosa et al. [13]. Melting curve analysis was 
always performed at the end of each assay as a specificity 
control.
Primer design
All genes included in the study encode proteins described 
a priori as specific for gametocyte stages. mRNA gene 
sequences were retrieved from PlasmoDB database and 
used as templates to design qPCR primers using the Primer 
Express Software v.1.5 (Applied Biosystems) (Table 2).
Data analysis
Threshold cycle (Ct) values from the measurement of the 
cDNA samples were obtained in duplicate using the 7000 
and the 7500 fast system Software (Applied Biosystem) 
and further analysed using an excel data sheet (Microsoft 
Corporation). The average value was taken as the result 
and only duplicate Ct values within ±1 Ct difference 
were accepted. Ct values were used to quantify the rela-
tive amount of target PCR product present in each reac-
tion; values are inversely proportional to the amount of 
template in the sample.
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Fig. 1 Scheme showing the cidal vs static in vitro activity assay against stage V Plasmodium falciparum gametocytes. Gametocytes were incubated 
for 48 h with 20 × IC50. After drug was washed out, the parasites were cultured for 96 h with complete culture medium with drug (A) or without 
drug (B) to evaluate the reversibility of compound effects. Two samples at t = 0, 48, 96, and 144 h were taken for RNA extraction, cDNA synthesis 
and qPCR amplification. Comparison of mRNA levels of treated P. falciparum cultures upon removal of the drug was used to assess the cidal vs static 
activity
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Table 1 Characteristics of the anti-malarial compounds tested in the assay
Compounde Structure P.f. gametocytes  
IC50 (µM)
TOX50 (µM)b Assay concentration  
(µM)c
Chloroquined – 23.47 51.84 5.00
Methylene blue – 0.49 6.52 5.00
Dihydroartemisinin – 3.56 >50 71.20
Epoxomicin – 0.0005 0.003 0.001
Thiostrepton – 0.90 – 18.00
TCMDC‑134278 >5 19.95 NT
TCMDC‑136869 1.66 12.59 NT
TCMDC‑125520 0.0098 12.80 0.20
TCMDC‑123475 0.0098 >25 0.20
TCMDC‑125133 0.54 >50 10.76
TCMDC‑125769 0.04 >25 0.86
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Gene expression during gametocytogenesis was rep-
resented with an adaptation of the method described 
by Livak and Schmittgen as (Ctgene−Ct18S rRNA)Ttime × −
(Ctgene−Ct18S rRNA)T0, considering the expression at time 
0 (T0) as the basal expression and using the 18S rRNA 
gene as housekeeping gene [25]. Absolute quantification 
(direct comparison of Ct values) was considered the most 
appropriate method for the drug activity assays.
Results
Identification and validation of genes expressed 
in late‑stage gametocytes
In order to confirm expression profiles of genes specific 
to the later stages of gametocyte development during the 
gametocytogenesis process [24], a selection of 12 genes 
previously described in the literature as being gametocyte 
specific were selected (Table 2). Initially, the transcription 
Table 2 Differentially expressed genes in the parasite life cycle, and primers for qPCR
a Gene identification number from PlasmoDB
b Primers designed using the Primer Express Software (Applied Biosystems). Pfs16 and Pfs25 primers designed by Schneider et al. [21]
Gene IDa Description Primersb
Housekeeping gene
 18S rRNA 18S ribosomal RNA (PF3D7_0112300) AATAACAATGCAAGGCCAATTT CTGCAACAATTTTAATATACGC
Young gametocytes
 PFD0310w Sexual stage‑specific protein precursor (Pfs16) AGTTCTTCAGGTGCCTCTCTTCA
AGCTAGCTGAGTTTCTAAAGGCA
 PF14_0748 Exported protein (PHISTa), unknown function (Pfg14‑748) CTTATGTGCTGAATTTTGTGTTATGGT TGTAAACTCTGATTTGGCCACACT
 PF13_0011 Gamete antigen 27/25 (Pf 27\25) CATGAAACACATGCCCCTCTCT GCTACAGGCATGAAACTCAATATCC
 PF14_0744 Exported protein, unknown function (Pfg14‑744) TTATGTATAATGGCTCTGTTGACGG GGCTTCTCGACTTCCTCGAA
 PFL0795c Male development gene 1 (Pfmdv‑1/peg3) TTTGAGACATTTGAACAAGCTTTACA GCATTTCCGGATTTGTTATTTTC
 PF10_0164 Early transcribed membrane protein 10.3 (ETRAMP10.3) TGCTGCTGTTGCTTTGGCTA CCTCAGAGTCGGATCCATCATT
Mature gametocytes
 PFF1035w (Pf77) GGAAGACAAAAAACACTGCACATTA
TTCAAACCATCGTCCTCTTTTTC
 PFL2405c Female specific gametocyte‑specific (Pfg377) TGTTCTTTTTCATATCGTCTATCTTCCT
TTGCTTTCCTTAAGATGTTTAATGATG
 PF10_0303 25 kDa ookinete surface antigen precursor (Pfs25) GACTGTAAATAAACCATGTGGAGA CATTTACCGTTACCACAAGTTA
 PFL2510w Chitinase (pfcht1) TCGAGCACGACCAGGTGAA
CCTTTCCCACTCTCTTTAAATGTTTT
 PF10_0302 28 kDa ookinete surface protein (Pfs28) AGAAAATGAAGTGTGTACATTAGAAGGAA
GATGTATCAGCCTGGTCCACAGT
 MAL8.P1.16 Rhomboid protease ROM3 (ROM3) AAACTTGAGCACACCAAATGTTCAT
CGGTAGCACAAGTCTCCAATATTG
a IC50 values measured in the laboratory for 3D7A P. falciparum mature gametocytes with the ATP bioluminescence assay [24]
b Cytotoxicity data using the short‑term resazurin‑based reductase assay [24]
c Working concentrations were 20 × IC50 if that was below the TOX50
d Working concentration of chloroquine was 5 µM corresponding to ×125 the asexual IC50
e GSK compounds were published in Ref. [23]
Compounde Structure P.f. gametocytes  
IC50 (µM)
TOX50 (µM)b Assay concentration  
(µM)c
TCMDC‑125114 0.13 >50 2.60
Table 1 continued
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profile of those genes throughout a gametocytogenesis 
process using the qPCR technique was investigated. The 
experiment was done in duplicate for 15 days, with one 
arm extended up to 30 days to determine the stability of 
the mRNAs once mature gametocytes were developed. 
Results corresponding to the 30-day assay are presented, 
as similar results were obtained in both assays during the 
first 15  days. Results were normalized with the house-
keeping gene (18S rRNA) and then referenced to time 0. 
Genes with increasing expression were represented by 
negative Ct values.
Although all the 12 selected genes had been described 
as stage-specific in the literature, only the sub-set of 
genes coding for Pfs25, ROM3, Pfg377, Pf77, Pfs16, and 
Pf 27/25 showed a temporal increase in expression dur-
ing gametocytogenesis when analysed using qPCR (Fig. 2; 
Additional file 1). Among the genes previously described 
as specific of early gametocyte stages, only genes coding 
for proteins Pfs16 and Pf 27/25 showed an increase in 
expression at day 4 of gametocytogenesis with the major-
ity of the gametocytes at stage I and II (Fig. 2). After day 
7, mRNA levels of these genes remained stable. In the 
case of the genes previously described as specific for the 
later stages of gametocyte development, only the ones 
coding for Pfs25, ROM3, Pfg377 and Pf77 were identified 
as specific for mature gametocytes (Fig. 2). However, the 
magnitude of the change in expression levels was differ-
ent among the different genes. ROM3, Pfg377 and Pf77 
protein coding genes showed an increase in expression 
starting around day 10 up to day 20 of approximately 6 
Ct (100-fold change when compared to the basal levels 
at day 0), with expression levels stabilizing after day 20. 
When using qPCR, a difference of 3 Cts corresponds to 
an approximately tenfold change in the total amount of 
cDNA (Additional file  2). In comparison, expression of 
the Pfs25 protein gene showed a variation of 10 Ct until 
day 20 before stabilizing (ca. 1000-fold increase).
Using standard protocols for the in vitro development 
of gametocytes, there is a longer co-existence of asexual 
and sexual stages during the process. Therefore, a new 
gametocytogenesis protocol was carried out using bis-
tratene A from day 4 until the end of the experiment to 
remove asexual parasites earlier. The gene expression 
analysis of these new samples is represented in Fig.  3a, 
with results confirming what was observed in the pre-
vious assay, but with a smaller increase in expression of 
genes coding for proteins Pfs16 and Pf 27/25 at day 5, 
because of the earlier elimination of asexual parasites. 
An additional representation of the data as heat map was 
also generated (Fig. 3b). Genes expressed in early game-
tocytogenesis had a maximum expression at day 7 and 
genes specific to the later stages of gametocyte develop-
ment (stages IV and V) peaked at days 15–20. This result 
confirmed that the genes for proteins ROM3, Pfg377, 
Pf77, and Pfs25 were highly expressed in the later stages 
of gametocyte development, and could be used for ana-
lysing drug gametocytocidal activity.
Determination of gametocytocidal activity of standard 
anti‑malarial drugs
Gametocytocidal activity of anti-malarial drugs was 
investigated using a similar method to that previously 
described for asexual stages [13]. Two different treat-
ments were performed in parallel, one with constant 
drug pressure throughout the experiment (T∞), 144 h in 
total, and another in which the gametocyte cultures were 
exposed to the compound for only 48  h, the drug was 
washed out and then cultured for a further 96 h in fresh 
complete culture medium (T48) (see Fig. 1).
The assay was validated against standard anti-malarial 
drugs: epoxomicin (EX), dihydroartemisinin (DHA), 
chloroquine (CQ), thiostrepton (TS) and methylene blue 
(MB). Results corresponding to the Pf77 coding gene are 
presented (Fig. 4a), though profiles for ROM3 and Pfg377 
behaved similarly (Additional file  3). As expected, CQ 
treatment did not affect mature gametocytes and the Ct 
values were similar to the untreated control, even when 
CQ treatment was maintained during the whole experi-
ment (Fig. 4a). DHA, TS and EX treatments resulted in 
an increase in at least 5 Ct values in samples with drug 
present for 144 h (T∞), indicative of a minimum decrease 
of ca. 100-fold in mRNA levels. However, if drug was 
only present for 48  h (T48), mRNA levels were reduced 
less than tenfold after drug removal, suggesting a static 
behaviour of the compounds. In the case of MB, the 
decrease in mRNA levels initiated during the first 48  h 
of treatment continued independently of whether con-








































Fig. 2 Graphic representation of gene expression throughout the 
30 days of gametocytogenesis. Y axis shows gene expression repre‑
sented as (Ctgene−Ct18S rRNA)Ttime × −(Ctgene−Ct18S rRNA)T0, consider‑
ing the time 0 as the basal expression. Among the 12 genes analysed 
only the ones shown in the graph had a clear kinetic profile
Page 7 of 11Bahamontes‑Rosa et al. Malar J  (2016) 15:385 
removed after 48 h of treatment (T48), suggesting a cidal 
effect of the drug. Thus, measurement of specific mRNA 
levels can be used as surrogate of the activity of com-
pounds acting against later stages of gametocyte devel-
opment. Furthermore, the differential profile of mRNA 
expression obtained from constant drug pressure vs 48-h 
exposure could be used to characterize the cidality of the 
anti-malarial effects of compounds against gametocyte 
stages.
The assay was further tested against a panel of com-
pounds selected from the GSK compound collec-
tion (Table  1). The compounds TCMDC-125520, 
TCMDC-123475, TCMDC-125133, TCMDC-125769, 
and TCMDC-125114 have demonstrated anti-malarial 
activity against asexual stages [23] and against late-stage 
gametocytes [24]. In addition to these molecules, a close 
derivative of TCMDC-136869, a quinolone-like com-
pound (COMP 2) displaying an IC50 of 0.58 µM against 
mature gametocytes, was also included in the experi-
ment. As negative control, a close derivative of TCMDC-
134278, an azol-like compound (COMP 1) was included, 
which has no activity against mature gametocytes (IC50 
>2  µM). Gene expression profiles in response to com-
pound treatment are described in Fig.  4b and Addi-
tional files 4 and 5. Compounds TCMDC-125520 and 
TCMDC-125769 showed similar profiles and data only 
for TCMDC-125769 are shown in Fig.  4b with the pro-
tein Pf77 gene. A constant increase in the Ct values (5 Ct 
Fig. 3 Stage‑specific gene expression. Graphic representation of gene expression in gametocytogenesis using bistratene A to remove asexual 
stages from day 4. Gene expression profile represented: a as (Ctgene−Ct18S rRNA)Ttime × −(Ctgene—Ct18S rRNA)T0, considering the time 0 as the basal 
expression; b in a heat map with an individual colour scale from the lowest expressed (red) to the highest expressed (dark green) levels
Fig. 4 Graphic representation of the Ct values of the Pf77 coding gene after treatment with a standard anti‑malarial drugs or b compounds from 
the GSK collection. Only protein Pf77 gene is represented, but all genes tested (ROM3 and Pfg377) behaved similarly. Two different protocols were 
used: T48 corresponds to the cultures where compounds were removed after 48 h and replaced by complete media; T∞ indicates that cultures 
were maintained with drug pressure throughout the 144 h of the experiment
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approximately, ca. 100-fold change) was observed when 
the compounds were maintained throughout the experi-
ment. However, Ct values after drug removal (T48) only 
increased a maximum of 2 Ct (less than tenfold change) 
indicating a static effect. A similar profile, although with 
a higher Ct increase (7 Ct, more than 100-fold change), 
was obtained for compounds TCMDC-125114, TCMDC-
123475 and TCMDC-125133 (only TCMDC-125114 is 
shown in Fig. 4b with protein Pf77 gene). COMP 2 dis-
played a different expression profile, with an increase of 
3 Ct (tenfold change) at 96 h that remained stable inde-
pendently of whether drug pressure was maintained or 
withdrawn. Finally, mRNA levels of cultures with com-
pound COMP 1 (negative control) showed no difference 
compared with the control or the CQ-treated culture, as 
expected.
In summary, TCMDC-125520, TCMDC-123475, 
TCMDC-125133, TCMDC-125769, and TCMDC-
125114, which were identified as having activity against 
gametocytes using an ATP gametocytocidal assay [8], 
showed a prolonged reduction in mRNA levels only 
when the drug was continuously present during the 
whole experiment.
Determination of minimal gametocytocidal concentration
Considering that TCMDC-125114 displayed the strong-
est effects against mature gametocytes, a new experi-
ment was done to estimate the minimal concentration 
needed to produce the maximal biological effect against 
mature gametocytes. This information determined the 
maximum potential of the compound. Concentrations 
of TCMDC-125114 at 20  ×  IC50, 60  ×  IC50 and 
100  ×  IC50, and for CQ of 2  ×  IC50, 20  ×  IC50 and 
125  ×  IC50 values in asexual stages (negative con-
trol) were evaluated as described above, with 48  h of 
drug treatment only. However, a culture treated with 
20 × IC50 of TCMDC-125114 during the whole experi-
ment (T∞) was included as a positive control to achieve 
inhibition.
As expected, no Ct increase was obtained with CQ 
at any concentration tested (Fig.  5a). In comparison, 
TCMDC-125114 elicited an increase in the Ct values at 
48  h. Increase was proportional to the concentration of 
drug used (Fig.  5b). At concentrations of 100 ×  IC50, a 
continuous increase in the Ct values was observed even if 
drug was removed after the initial 48 h, indicative of cidal 
activity (Fig. 5b).
Discussion
Effective treatments aimed at reducing malaria transmis-
sion would have a considerable impact on malaria con-
trol efforts and significantly reduce the burden of disease. 
In vitro assays against sexual stages are essential for the 
identification and characterization of new anti-malarial 
chemotypes with transmission-blocking activity. In rec-
ognition of the extensive work done to produce mature 
gametocytes in a reproducible manner, the anti-malar-
ial community has now acquired the tools to test anti-
malarial drugs against the parasite stage relevant for 
transmission. Several approaches assessing drug activity 
against gametocytes have been developed [6, 7, 11, 12, 24, 
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Fig. 5 Minimal concentration for cidal effect of TCMDC‑125114 with the Pf77 coding gene. With drug exposure for 48 h, increasing concentrations 
were tested of: a chloroquine (negative control); or b TCMDC‑125114 (active against gametocytes). TCMDC‑125114 was used at 20 × IC50 during all 
the experiments; TCMDC‑125114 20 × IC50 with drug exposure throughout the 144 h of the experiment (T∞) was used as a positive control
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imaging-based HTS assay, based on the ability of mature 
gametocytes to progress to gametes after drug exposure. 
The current study described a new assay to support the 
characterization of any anti-malarial at the drug discov-
ery process that could be used on sexual and asexual 
stages.
The current study described six genes differentially 
expressed at specific gametocyte stages, four of which 
were highly expressed in later stages of gametocyte 
development. Identification of these genes allowed the 
discrimination of drug activity against late-stage gameto-
cytes by molecular methods. The use of molecular mark-
ers for sex ratio estimation and sexual stage identification 
has been described previously [18, 22]. Quantification 
of female and male gametocytes by qPCR relied on the 
expression of Pfs25 and Pfs230p protein genes for female 
and male, respectively [22], and the transcriptome of 
gametocytes from stage I to V was profiled using micro-
arrays [18]. In accordance with previously published 
studies, the results described in this paper confirm Pfs16 
as the most appropriate marker to detect early gameto-
cytogenesis [20, 21] with a profile similar to the one pub-
lished by Adjalley et  al. [11], and expression of ROM3, 
Pfs25, Pf77, and Pfg377 as the best surrogates to study 
later stages of gametocyte development [11, 19–21, 27]. 
Pfs25 was described as expressed exclusively in female 
mature gametocytes [22], and this is in accordance with 
the results obtained in this publication, as mixed sexual 
gametocyte stage cultures were used.
Previously, qPCR has been shown to be a very potent 
tool, easy to perform and implement, which can be focused 
on specific parasite stages [19]. In the methods described 
in this paper, stage-specific mRNA expression levels, deter-
mined using qPCR, were used as a surrogate for parasite 
viability. The method was validated against anti-malarial 
drugs and research compounds with known activity against 
gametocytes. Consistent with previous reports, CQ did not 
show any activity against gametocytes at any of the concen-
trations tested [28]. For DHA, EX and TS, although there 
was a reduction in late-stage gametocyte mRNA levels after 
48-h of treatment, this effect persisted only when the drugs 
were present in the culture media. In contrast, with MB 
the reduction in the gene expression was maintained even 
after drug removal, indicating gametocytocidal activity, and 
this is consistent with published data [7, 11]. In fact, MB 
was reported to be a very effective gametocytocidal agent 
against gametocyte stages I-V, and has a striking impact 
on transmission in mosquitoes fed on treated gametocytes 
[7, 11]. On the other hand, DHA has been reported to be 
poorly potent against mature sexual stages using an ATP 
measurement read-out [24], and high concentrations 
were needed to see an effect. It has been also reported 
that mature male gametocytes are more sensitive to DHA 
[26]. The response observed here with DHA could be 
explained by the concentration used in the assay that cor-
responded to 20 times the IC50 and the methodology used 
that quantifies only gametocyte mRNA levels. The results 
obtained with GSK compounds confirmed their activity 
previously described against gametocytes using an alterna-
tive methodology [8, 24]. The majority: TCMDC-125520, 
TCMDC-123475, TCMDC-125133, TCMDC-125769, 
and TCMDC-125114, behaved as the commercial anti-
malarial drugs TS and EX with the exception of COMP 
2 that showed an irreversible effect, although only for 
an additional 48 h after drug removal. The in vitro game-
tocytocidal activity of compound TCMDC-125133 and 
TCMDC-125114 were previously validated ex  vivo using 
the SMFA with a 100 % reduction in the number of oocysts 
when assayed at 2.5 µM [8].
Dose–response relationships can also be investi-
gated using the described assay, as shown for CQ and 
TCMDC-125114, and are needed to determine the mini-
mal amount of compound required to produce maximal 
biological effect. Such studies indicate the biological rel-
evance of findings of anti-gametocyte drug activity, as the 
potential toxic effects provoked by high compound con-
centrations must be considered.
Conclusion
The development of compounds with cidal activ-
ity against mature gametocytes is essential for malaria 
eradication. However, screening for Plasmodium trans-
mission-blocking drugs has been very time consuming 
and typically relied on laborious techniques or expen-
sive devices [11, 24, 27, 29]. This study describes a novel 
assay for characterizing the activity of anti-malarial drugs 
against non-engineered unmodified P. falciparum late-
stage gametocytes using qPCR. The assay analyses the 
effects of exposing the parasites to a full inhibitory dose 
of an anti-malarial drug on the mRNA levels of genes 
specifically expressed in late gametocyte stages. The 
method described is a reliable and user-friendly tech-
nique with a medium throughput that could be easily 
implemented in any laboratory. Moreover, samples can 
be stored and processed afterwards, even in a different 
reference laboratory to where the assays were performed.
Page 10 of 11Bahamontes‑Rosa et al. Malar J  (2016) 15:385 
Authors’ contributions
NB conceived and designed the study, carried out laboratory experiments, 
conducted data management and data analysis, and wrote the manuscript. 
MG conceived and designed the study, conducted data management and 
data analysis. JL participated in the study design, supported the gametocyte 
work and interpretation of data. AR supported the qPCR and the anti‑malarial 
assays. MJA and SL performed the gametocytogenesis. FJG coordinated 
the study and participated in the data analysis and drafted manuscript. EH 
participated in the study coordination. All authors read and approved the final 
manuscript.
Acknowledgements
We are grateful to Mª Angeles Burgos for excellent collaboration in the 
preparation of media and buffer solutions. Editorial assistance was provided 
by Naomi Richardson of Magenta Communications Ltd and was funded by 
GlaxoSmithKline.
Competing interests
All authors are employees of GlaxoSmithKline. NB, MGGL, JL, MJA, SL, EH, and 
FJG own shares in the company.
Ethics approval and consent to participate
The human biological samples were sourced ethically and their research use 
was in accord with the terms of the informed consents.
Funding
The research in this paper was supported by GlaxoSmithKline.
Received: 7 April 2016   Accepted: 5 July 2016
Additional files
Additional file 1. Graphical representation of the expression of 12 
selected genes throughout the 30 days of gametocytogenesis. Y‑axis 
shows the gene expression represented as (Ctgene−Ct18S rRNA)Ttime × −
(Ctgene−Ct18S rRNA)T0, considering the time 0 as the basal expression. 
Although only the gametocytogenesis during 30 days is presented, similar 
results were obtained from day 0 to day 15 in both assays.
Additional file 2. Calibration curve for converting Ct values into fold 
changes in the total amount of cDNA. Note that when using qPCR, a dif‑
ference of 3 Cts corresponds to an approximately ten‑fold change in the 
total amount of cDNA.
Additional file 3. Graphic representation of the Ct values after treatment 
with standard anti‑malarial drugs. (A) Pfg377 protein coding gene; (B) 
ROM3. Two different protocols were used: T48 corresponds to the cultures 
where compounds were removed after 48 h and replaced by complete 
media; T∞ indicates that cultures were maintained with drug pressure 
throughout the 144 h of the experiment.
Additional file 4. Graphic representation of the Ct values after treatment 
with compounds TCMDC‑125769, TCMDC‑125114, COMP 1 and COMP 2 
from the GSK collection. (A) Pfg377 protein coding gene; (B) ROM3. Two 
different protocols were used: T48 corresponds to the cultures where com‑
pounds were removed after 48 h and replaced by complete media; T∞ 
indicates that cultures were maintained with drug pressure throughout 
the 144 h of the experiment.
Additional file 5. Graphic representation of the Ct values after treatment 
with compounds TCMDC‑125520, TCMDC‑123475 and TCMDC‑125133 
from the GSK collection with the protein coding genes: (A) Pfs77, (B) 
Pfg377 and (C) ROM3. Two different protocols were used: T48 corresponds 
to the cultures where compounds were removed after 48 h and replaced 
by complete media; T∞ indicates that cultures were maintained with drug 
pressure throughout the 144 h of the experiment.
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